Fig. 1 · Structure

Documents & Downloads

IU1

Cat. No. A13209 CAS 314245-33-5

Usp14 inhibitor

IU1 is a selective inhibitor of Usp14. It inhibits the catalytic activity of proteasome-associated Usp14 in vitro (IC50 < 4 uM).

In Stock

Publications for IU1

2 publications citing this product

  1. Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427
  2. Anurag Rathore, .et al. , Sci Rep, 2020, 10: 5350 PMID: 32210344

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

IU1 reversibly inhibits proteasome-associated USP14. In a Ub-AMC assay, its IC50 was 4.7 ± 0.7 μM (mean ± s.d., n=3); inhibition was weaker against IsoT and UCH37, and selectivity was assessed against a limited DUB panel. These biochemical findings do not establish proteome-wide selectivity. [1]

IU1 also directly inhibited mitochondrial Complex I activity in rat brain mitochondrial membranes: the reported IC50 for NADH:Q1 reductase was around 40 μM. Other respiratory activities changed at higher concentrations, so cellular responses at these exposures cannot automatically be attributed solely to USP14. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
USP14 4.7 μM

IU1 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of IU1 from 3 published references. In vitro models include permeabilized rat brain mitochondrial membranes.

IU1 In Vitro Studies

In Tau-expressing wild-type MEFs, six-hour IU1 exposure reduced Tau protein, with no corresponding reduction in Usp14-null MEFs. Proteasome-inhibitor controls antagonized Tau depletion, while the ubiquitin-independent substrate cODC-EGFP showed little or no response. [1]

Primary rat cortical neurons showed reduced MTT signal and ATP following IU1 exposure in concentration/time experiments. Co-treatment with PGJ2 further reduced these endpoints. This neuronal bioenergetic response limits extrapolation of the MEF findings; reduced MTT signal alone does not quantify neuronal loss. [2]

Reversible inhibition of proteasome-associated USP14

Biochemical assay · Recombinant human USP14 associated with Ub-VS-treated human 26S proteasomes; Ub-AMC hydrolysis [1]

IU1 inhibited proteasome-associated USP14. The tested DUB panel and recovery after compound removal support selectivity within that panel and reversible inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of proteasome-associated USP14 Ub-AMC hydrolysisIC50 4.7 ± 0.7 μM[1]
IsoT and UCH37 inhibition; broader DUB panelComparator IC50 IsoT: 100 ± 0.4 μM; UCH37: 0.7 ± 0.3 mM[1]
USP14 activity after removal of IU1Qualitative recovery Activity recovered after spin gel filtration[1]

Literature-Reported Treatment Conditions

Treatment concentration
Dose-response assay: 50 nM–100 μM IU1 for USP14; selectivity panel: 17 μM; reversibility: 100 μM
Exposure duration
IC50: 30 min preincubation followed by 45 min monitoring; reversibility exposure: 2 h
Method
Cell-free enzyme activity assays and compound-removal control
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: IU1; Compound label in the paper: IU1

Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.

Fig. 2a–d and caption; full Methods: DUB activity assay, IC50 value determination, IU1 reversibility test

Inhibition of proteasome-associated USP14 Ub-AMC hydrolysis: Mean ± s.d.; n=3. Enzyme/compound preincubation 30 min, 1 μM Ub-AMC; fluorescence monitored at room temperature for 45 min. — Fig. 2b caption; Methods: IC50 value determination

IsoT and UCH37 inhibition; broader DUB panel: Mean ± s.d.; n=3 in Fig. 2 caption. At 17 μM IU1, Fig. 2c compares USP14 with eight other DUBs; panel selectivity is not a proteome-wide selectivity claim. — Fig. 2b–c and caption; Methods: DUB activity assay

USP14 activity after removal of IU1: 60 nM USP14 and 5 nM human proteasome exposed to 100 μM IU1 or DMSO for 2 h; Ub-AMC activity assayed before/after filtration; mean ± s.d., n=3. No percentage inferred from bars. — Fig. 2d and caption; Methods: IU1 reversibility test

Tau response depends on USP14 and proteasome function in MEFs

Cell-based study · Wild-type and Usp14-null mouse embryonic fibroblasts transiently expressing Tau [1]

IU1 reduced Tau immunoblot signal in wild-type MEFs but not Usp14-null MEFs. Proteasome inhibitors antagonized the response, while the ubiquitin-independent substrate cODC-EGFP showed little or no response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tau protein abundance with IU1 in wild-type versus Usp14-null MEFsQualitative immunoblot outcome Dose-dependent reduction in wild-type MEFs; no Tau reduction in Usp14-null MEFs[1]
Proteasome dependence and substrate specificity of the Tau responseControl comparison Proteasome inhibitors antagonized Tau depletion; little or no effect on cODC-EGFP[1]

Literature-Reported Treatment Conditions

Treatment concentration
Wild type: 0, 25, 50, 75, 100 μM; Usp14-null: 0, 10, 50, 100 μM; proteasome-control experiment: 50 μM
Exposure duration
6 h
Method
Cell treatment followed by immunoblotting
Vehicle
Vehicle composition for the Fig. 4a–c cell experiment is not specified in the inspected caption/mammalian-culture subsection.
Co-treatment
Control experiment includes MG132 (30 μM) and PS-341 (10 μM); these are mechanistic controls, not an IU1 combination-efficacy claim.
Reported limits
Biological replicate count for these representative blots not stated in the inspected caption.
Methods and source locations

Compound reported in the paper: IU1; Compound label in the paper: IU1

Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.

Fig. 4a–c and caption; Results: A Usp14 inhibitor accelerates proteolysis in cells; Methods: Mammalian cell cultures and transient expression

Tau protein abundance with IU1 in wild-type versus Usp14-null MEFs: Six-hour exposure 36 h after cotransfection; LacZ transfection and actin loading controls. No fold-change or n inferred from representative blots. — Fig. 4a–b and caption

Proteasome dependence and substrate specificity of the Tau response: Wild-type MEFs coexpressing Tau/cODC-EGFP; 50 μM IU1 for 6 h; MG132 30 μM and PS-341 10 μM as proteasome-inhibitor controls. — Fig. 4c and caption; accompanying Results paragraph

IU1 reduces neuronal MTT signal and ATP under matched exposures

Cell-based study · Primary E18 Sprague Dawley rat cerebral cortical neurons (both sexes), experiments at 8–11 days in vitro [2]

Concentration/time experiments found reduced MTT signal and ATP after IU1 exposure. Separate combination comparisons with PGJ2 further reduced both endpoints. MTT is an assay of metabolic reduction and does not establish a direct neuron count.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Neuronal MTT reduction relative to DMSO controlQualitative concentration/time response Reduced signal; 5 μM IU1 for 24 h: p=0.005, n=12 (Results text)[2]
Steady-state ATP normalized to proteinQualitative concentration/time response ATP decreased with higher concentration and longer exposure; 25 μM plus 10 μM PGJ2 reduced ATP further[2]

Literature-Reported Treatment Conditions

Treatment concentration
24 h MTT series (Fig. 3A): 0, 5, 10, 25, 50 μM IU1; 24 h ATP series (Fig. 4A): 0, 5, 10, 25, 50, 75 μM IU1; time series: 25 μM; combination comparison: 25 μM IU1 with 10 μM PGJ2
Exposure duration
Concentration/comparison experiments: 24 h; time course: 4, 8, 16, 24 h
Method
Cell exposure; MTT and protein-normalized ATP assays
Vehicle
0.5% DMSO
Co-treatment
Separate IU1-alone, PGJ2-alone and IU1+PGJ2 groups; combination outcomes are attributed separately.
Reported limits
Exact response percentages are not reported here; substantial between-panel variability and ambiguous textual percent-loss wording preclude a single pooled estimate.
Methods and source locations

Compound reported in the paper: IU1; Compound label in the paper: IU1

Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.

Results 3.2; Figs. 3–4 and captions; Methods 2.1, 2.3–2.6, 2.16

Neuronal MTT reduction relative to DMSO control: Fig. 3 caption describes means and s.e. from at least three independent experiments/group; Results separately gives n=12 for 5 μM. Replicate hierarchy of that n is not clarified. One-way ANOVA with Tukey multiple comparisons in Methods. — Results 3.2; Fig. 3A–C and caption; Methods 2.5, 2.16

Steady-state ATP normalized to protein: Luciferin/luciferase assay; ATP in pmoles/μg protein; means and s.e., at least three independent experiments/group. Exact percentages not extracted: Results describes loss values inconsistently with its “of control” wording. — Fig. 4A–C and caption; Results 3.2; Methods 2.6

Direct mitochondrial Complex I inhibition

Biochemical assay · Permeabilized rat brain mitochondrial membranes [2]

IU1 inhibited NADH-oxidase and NADH:Q1 reductase activities of Complex I. The figure also shows weaker effects on other respiratory activities at higher concentrations, limiting a blanket claim of USP14-only pharmacology.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NADH:Q1 reductase activityIC50 around 40 μM[2]
Other mitochondrial respiratory activities at higher IU1 concentrationsQualitative comparison NADH:HAR activity decreased; succinate dehydrogenase changed modestly; Complex IV activity increased in the plotted data[2]

Literature-Reported Treatment Conditions

Treatment concentration
Fig. 5A–B concentration-response curves through 300 μM; Fig. 5C–E: 0, 120, 300 μM
Exposure duration
2 min preincubation before substrate addition
Method
Cell-free respiratory-chain activity measurements at 30°C
Vehicle
Vehicle for this mitochondrial assay is not explicitly identified in the Fig. 5 caption or Methods 2.7.
Methods and source locations

Compound reported in the paper: IU1; Compound label in the paper: IU1

Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.

Results 3.3; Fig. 5A–E and caption; Methods 2.1, 2.7, 2.16

NADH:Q1 reductase activity: Approximate value explicitly stated in Results; not fitted from the viewed curve. Spectrophotometry at 30°C after 2 min IU1 preincubation; mean ± S.D., at least 3 independent experiments. — Results 3.3; Fig. 5B and caption

Other mitochondrial respiratory activities at higher IU1 concentrations: 120 and 300 μM IU1 compared with 0 μM. Fig. 5D marks 120 μM ns and 300 μM ***, while Fig. 5E marks increases at 120 μM ** and 300 μM ***. Caption: **p<0.01; ***p<0.001; mean ± S.D., at least 3 independent experiments. No exact magnitudes inferred. — Fig. 5C–E and caption; Results 3.3

IU1 In Vivo Studies

In a mouse focal cerebral ischemia model, IU1 (400 μg/kg intraperitoneally, initially 2 h after 1 h MCAO and then daily) was associated with improved seven-day survival and lower neurological deficit scores from day 3. Average body weight did not differ significantly from vehicle. These findings are specific to the reported model and regimen. [3]

Post-ischemic IU1 and seven-day mouse outcomes

Animal study · Adult male C57BL/6 mice, 2–3 months old, after transient focal cerebral ischemia (1 h MCAO) [3]

Post-ischemic IU1 treatment was associated with improved survival and lower neurological deficit scores through day 7, while average body weight did not differ significantly from vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival over seven daysMedian survival time Vehicle: 5 days; IU1: more than 7 days[3]
Modified neurological severity score (lower scores indicate better function)Direction and significance Lower scores with IU1 from day 3 through day 7; *p<0.05[3]
Average body weight after strokeNegative finding No significant treatment-group difference within seven days[3]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Initial injection 2 h after 1 h MCAO; same dose daily thereafter
Treatment course
Follow-up through day 7
Vehicle
Saline vehicle comparator
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Post-ischemic IU1
400 μg/kg
Equal volume of salineDescriptively improved survival and lower neurological scores from day 3; no significant average body-weight difference.[3]
Post-ischemic IU1
Model: Adult male C57BL/6 mice after 1 h MCAO
Reported limits: No measured brain IU1 concentration; n=7–8 per group with survival attrition.
Methods and source locations

Compound reported in the paper: IU1; Compound label in the paper: IU1

Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.

Fig. 2A–C and caption; Results: IU1 enhances functional recovery; Methods: Animals, MCAO, Drug treatments, Statistical analysis

Survival over seven days: n=7–8 in each group; medians explicitly stated in Results. No survival-test p-value supplied in Fig. 2 caption; survival difference retained descriptively. — Fig. 2B caption; Results: IU1 enhances functional recovery

Modified neurological severity score (lower scores indicate better function): Caption reports median value ± SEM, n=7–8, Tukey test. Preserve the unusual reported summary semantics; no numerical score read from the graph. — Fig. 2C caption; Results: IU1 enhances functional recovery; Table 1 definition

Average body weight after stroke: Both groups lost weight; caption reports Mean ± SEM, n=7–8 for each group. No exact weights inferred. — Fig. 2A and caption; Results: IU1 enhances functional recovery

Post-ischemic IU1 · Fig. 2A–C and caption; Drug treatments; IU1 enhances functional recovery

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 314245-33-5
Applications Usp14 inhibitor
Formula C18H21FN2O
Molecular Weight 300.37
SMILES
CC1=CC(=C(N1C2=CC=C(C=C2)F)C)C(=O)CN3CCCC3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 51 mg/mL (169.79 mM)
Water Insoluble
Ethanol 51 mg/mL (169.79 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

IU1 Research References

  1. [1] Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature (2010). PMID: 20829789 DOI: 10.1038/nature09299 Source material
  2. [2] Kiprowska MJ, Stepanova A, Todaro DR, et al. Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochimica et biophysica acta. Molecular basis of disease (2017). PMID: 28372990 DOI: 10.1016/j.bbadis.2017.03.017 Source material
  3. [3] Min JW, Lü L, Freeling JL, et al. USP14 inhibitor attenuates cerebral ischemia/reperfusion-induced neuronal injury in mice. Journal of neurochemistry (2017). PMID: 28029679 DOI: 10.1111/jnc.13941 Source material

Publications

2 publications citing this product

  1. Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427
  2. Anurag Rathore, .et al. , Sci Rep, 2020, 10: 5350 PMID: 32210344

Added to your cart

View Cart Checkout
Loading...